Vaxxinity Inc
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial … Read more
Vaxxinity Inc (VAXX) - Total Assets
Latest total assets as of March 2024: $44.31 Million USD
Based on the latest financial reports, Vaxxinity Inc (VAXX) holds total assets worth $44.31 Million USD as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vaxxinity Inc - Total Assets Trend (2019–2023)
This chart illustrates how Vaxxinity Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vaxxinity Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Vaxxinity Inc's total assets of $44.31 Million consist of 75.0% current assets and 25.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.1% |
| Accounts Receivable | $414.00K | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2023)
This chart illustrates how Vaxxinity Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaxxinity Inc's current assets represent 75.0% of total assets in 2023, a decrease from 90.0% in 2019.
- Cash Position: Cash and equivalents constituted 11.1% of total assets in 2023, down from 29.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.9% of total assets.
Vaxxinity Inc Competitors by Total Assets
Key competitors of Vaxxinity Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Vaxxinity Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Vaxxinity Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Vaxxinity Inc is currently not profitable relative to its asset base.
Vaxxinity Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.89 | 2.77 | 0.96 |
| Quick Ratio | 1.89 | 2.60 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $15.62 Million | $ 46.97 Million | $ -1.55 Million |
Vaxxinity Inc - Advanced Valuation Insights
This section examines the relationship between Vaxxinity Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -58.4% |
| Total Assets | $44.31 Million |
| Market Capitalization | $1.27 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vaxxinity Inc's assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vaxxinity Inc's assets decreased by 58.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vaxxinity Inc (2019–2023)
The table below shows the annual total assets of Vaxxinity Inc from 2019 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $44.31 Million | -58.35% |
| 2022-12-31 | $106.40 Million | -36.16% |
| 2021-12-31 | $166.67 Million | +232.41% |
| 2020-12-31 | $50.14 Million | +3043.64% |
| 2019-12-31 | $1.59 Million | -- |